Anne Wojcicki
Angel Investor
San Francisco, United States
Anne Wojcicki is a seed investor in San Francisco focused on Health Care and Medical. Anne Wojcicki is the Co-Founder and CEO of 23andMe. She previously worked at Passport Capital as a Healthcare Analyst. Anne Wojcicki attended Yale University.
- Total investments:
- 65
- Last investment:
- Lead investor:
- 2%
Last updated:
For AI agents: llms.txt
Industries Anne Wojcicki invests in
Stages Anne Wojcicki invests in
Countries Anne Wojcicki invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1M–$12M
- Series A
- $7M–$70M
- Series B
- $19M–$63M
Investment Focus
Industry
- Health Care 36 (55%)
- Medical 15 (23%)
- Biotechnology 9 (14%)
- Artificial Intelligence 8 (12%)
- Software 7 (11%)
Stage
- Seed 19 (29%)
- Series A 18 (28%)
- Series B 12 (18%)
- Series C 5 (8%)
- Pre-Seed 3 (5%)
Country
- United States 51 (78%)
- United Kingdom 3 (5%)
- Canada 1 (2%)
- Israel 1 (2%)
- Nigeria 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Nix makes biosensors that analyze electrochemical biomarkers to deliver health and wellness data to consumers. Its first consumer product is a skin patch that analyzes sweat to provide athletes, soldiers, and laborers with personalized hydration guidance in real time, helping them optimize performance and prevent dehydration. | $10M / Series A / Sep 15, 2026 | ||
| Clair Health is a health technology company developing a wearable device that functions as a continuous, non-invasive hormone monitor designed specifically for women. | $11.6M / Seed / Jun 17, 2026 | ||
| ScaleIP is an IP business intelligence platform that helps companies monetize IP. | $4M / Pre-Seed / Nov 05, 2025 | ||
World Labs
|
World Labs is an AI startup that can analyze visual data with comprehension akin to a person's, a substantial advancement above existing capacities. | $230M / Venture - Series Unknown / Sep 13, 2024 | |
| Solace is a digital health platform that connects patients with expert healthcare advocates. Their health advocates are former doctors, nurses, pharmacists, and other clinical and experience-driven professionals who navigate patients through healthcare challenges. | $14M / Series A / Aug 22, 2024 | ||
| Endo Health creates a gamified "AI endocrinologist" for type 2 diabetes management. They are creating a pleasant AI medical assistant that will walk patients through every stage of diabetic control, complete with gamified involvement. | $1M / Pre-Seed / Jun 25, 2024 | ||
| Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $33M / Series B / May 29, 2024 | ||
| Midi Health provides virtual healthcare services focused on midlife women’s health, especially around hormonal changes such as perimenopause and menopause, through personalized care plans delivered by clinicians trained in these areas. Its services include telehealth consultations that can integrate prescription support, supplements, lifestyleguidance, and symptom-specific treatments to address issues like weight, mood, sleep, and sexual wellness. Midi Health also offers tailored support protocols that consider an individual’s health history and goals to guide ongoing care. Its platform makes care accessible online and works with insurance for coverage of visits and prescriptions. The company additionally offers targeted supplements designed to complement its clinical care approach. | $63M / Series B / Apr 24, 2024 | ||
| Brightside Health is a mental health care company that helps employees better navigate and manage their financial well-being. The company makes it simple and affordable to get expert, personalized treatment for depression and anxiety all from the comfort of home. Their mission is to help people lead healthy, vital, and productive lives by making iteasy and affordable to get high-quality depression and anxiety care.Brightside was founded in 2017 and is headquartered in San Francisco, California, United States. | $33M / Series C / Mar 26, 2024 | ||
| Ezra has created a new way to screen for cancer using full-body MRI technology assisted by Artificial Intelligence. The company's first AI, developed to assist radiologists when interpreting MRI images of the prostate, is an FDA-cleared software as a medical device. | $21M / Series B / Feb 07, 2024 | ||
| See all 65 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Anne Wojcicki invest in?
Anne Wojcicki invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 65 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Anne Wojcicki's check size?
Anne Wojcicki typically joins rounds of $1M–$12M at Seed, $7M–$70M at Series A and $19M–$63M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Anne Wojcicki participates in.
How do I contact Anne Wojcicki?
Public channels for Anne Wojcicki include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Anne Wojcicki last invest?
The most recent investment recorded for Anne Wojcicki closed in Sep 2026. Shizune tracks 65 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
